+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myc Proto Oncogene Protein - Pipeline Review, H1 2020

  • ID: 5017483
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biogenera SpA
  • Gibson Oncology LLC
  • Kronos Bio Inc
  • LA Cell Inc
  • MecRx Pty Ltd
  • OncoViRx LLC
  • MORE
Myc Proto Oncogene Protein - Pipeline Review, H1 2020

Summary

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Myc Proto Oncogene Protein - Pipeline Review, H1 2020, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication.

Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication. The molecules developed by companies in Preclinical and Discovery stages are 7 and 5 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Lymphoma, Breast Cancer, Hematological Tumor, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Chondrosarcoma, Colon Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemia, Lung Cancer, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma and T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).

Furthermore, this report also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
  • The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biogenera SpA
  • Gibson Oncology LLC
  • Kronos Bio Inc
  • LA Cell Inc
  • MecRx Pty Ltd
  • OncoViRx LLC
  • MORE
  • Introduction
  • Report Coverage
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
  • Biogenera SpA
  • Escend Pharmaceuticals Inc
  • Gibson Oncology LLC
  • Kronos Bio Inc
  • LA Cell Inc
  • MecRx Pty Ltd
  • OncoViRx LLC
  • Peptomyc SL
  • PYCTX Ltd
  • Sorrento Therapeutics Inc
  • Suzhou Kintor Pharmaceuticals Inc
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
  • Amy-22 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BGA-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Inhibit MYC for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ES-4000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
  • Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
  • Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
  • Mar 14, 2019: A new approach to drugging a difficult cancer target
  • Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
  • Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Biogenera SpA, H1 2020
  • Pipeline by Escend Pharmaceuticals Inc, H1 2020
  • Pipeline by Gibson Oncology LLC, H1 2020
  • Pipeline by Kronos Bio Inc, H1 2020
  • Pipeline by LA Cell Inc, H1 2020
  • Pipeline by MecRx Pty Ltd, H1 2020
  • Pipeline by OncoViRx LLC, H1 2020
  • Pipeline by Peptomyc SL, H1 2020
  • Pipeline by PYCTX Ltd, H1 2020
  • Pipeline by Sorrento Therapeutics Inc, H1 2020
  • Pipeline by Suzhou Kintor Pharmaceuticals Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biogenera SpA
  • Escend Pharmaceuticals Inc
  • Gibson Oncology LLC
  • Kronos Bio Inc
  • LA Cell Inc
  • MecRx Pty Ltd
  • OncoViRx LLC
  • Peptomyc SL
  • PYCTX Ltd
  • Sorrento Therapeutics Inc
  • Suzhou Kintor Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll